Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Status: Enrolling
Updated:  11/23/2010
Weill Medical Cornell University
mi
from
New York, NY
Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Status: Enrolling
Updated: 11/23/2010
Weill Medical Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Status: Enrolling
Updated:  11/23/2010
Stony Brook Cancer Center (SUNY)
mi
from
Stony Brook, NY
Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Status: Enrolling
Updated: 11/23/2010
Stony Brook Cancer Center (SUNY)
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Status: Enrolling
Updated:  11/23/2010
Providence Portland Medical Center
mi
from
Portland, OR
Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Status: Enrolling
Updated: 11/23/2010
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Status: Enrolling
Updated:  11/23/2010
Abramson Cancer Center of Uof Pennsylvania
mi
from
Philadelphia, PA
Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Status: Enrolling
Updated: 11/23/2010
Abramson Cancer Center of Uof Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Status: Enrolling
Updated:  11/23/2010
West Virginia University Clinical Trials Research Unit
mi
from
Morgantown, WV
Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Status: Enrolling
Updated: 11/23/2010
West Virginia University Clinical Trials Research Unit
mi
from
Morgantown, WV
Click here to add this to my saved trials
64CuATSM and Hypoxia in Stage IV Non-small Cell Lung Cancer With Carboplatin, Paclitaxel, and Bevacizumab
A Pilot Study of 64CuATSM and Hypoxia in Stage IV Non-small Cell Lung Cancer Patients Treated With Carboplatin, Paclitaxel, and Bevacizumab
Status: Enrolling
Updated:  2/25/2011
Washington University School of Medicine
mi
from
Saint Louis, MO
64CuATSM and Hypoxia in Stage IV Non-small Cell Lung Cancer With Carboplatin, Paclitaxel, and Bevacizumab
A Pilot Study of 64CuATSM and Hypoxia in Stage IV Non-small Cell Lung Cancer Patients Treated With Carboplatin, Paclitaxel, and Bevacizumab
Status: Enrolling
Updated: 2/25/2011
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors
A Phase II Clinical Trial of Cisplatin + Gemcitabine HCl (GEM) + Low-Dose Metronomic Interferon-a (IFN-a) Combined With Fever-Range Whole-Body Thermal Therapy (FR-WB-TT) in Patients With Metastatic/or Locally Advanced Malignancies (Small-Cell Lung Cancer, Neuroendocrine Cancer, Gastric Cancer)
Status: Enrolling
Updated:  3/2/2011
Memorial Hermann Hospital
mi
from
Houston, TX
Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors
A Phase II Clinical Trial of Cisplatin + Gemcitabine HCl (GEM) + Low-Dose Metronomic Interferon-a (IFN-a) Combined With Fever-Range Whole-Body Thermal Therapy (FR-WB-TT) in Patients With Metastatic/or Locally Advanced Malignancies (Small-Cell Lung Cancer, Neuroendocrine Cancer, Gastric Cancer)
Status: Enrolling
Updated: 3/2/2011
Memorial Hermann Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Erlotinib Hydrochloride in Treating Patients With Previously Treated Non-Small Cell Lung Cancer, Head and Neck Cancer, or Esophageal Cancer and Precancerous Lesions of the Lung
A Phase I Study of Erlotinib in Patients With Premalignant Lesions of the Lung
Status: Enrolling
Updated:  3/9/2011
Northwestern University
mi
from
Chicago, IL
Erlotinib Hydrochloride in Treating Patients With Previously Treated Non-Small Cell Lung Cancer, Head and Neck Cancer, or Esophageal Cancer and Precancerous Lesions of the Lung
A Phase I Study of Erlotinib in Patients With Premalignant Lesions of the Lung
Status: Enrolling
Updated: 3/9/2011
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Erlotinib Hydrochloride in Treating Patients With Previously Treated Non-Small Cell Lung Cancer, Head and Neck Cancer, or Esophageal Cancer and Precancerous Lesions of the Lung
A Phase I Study of Erlotinib in Patients With Premalignant Lesions of the Lung
Status: Enrolling
Updated:  3/9/2011
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Erlotinib Hydrochloride in Treating Patients With Previously Treated Non-Small Cell Lung Cancer, Head and Neck Cancer, or Esophageal Cancer and Precancerous Lesions of the Lung
A Phase I Study of Erlotinib in Patients With Premalignant Lesions of the Lung
Status: Enrolling
Updated: 3/9/2011
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Safety Study: Combined Modality Treatment for Non-Small Cell Lung Cancer
Phase 1 Toxicity/Feasibility Study: Combined Modality Treatment With Transimmunization for Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/21/2011
Morristown Memorial Hospital
mi
from
Morristown, NJ
Safety Study: Combined Modality Treatment for Non-Small Cell Lung Cancer
Phase 1 Toxicity/Feasibility Study: Combined Modality Treatment With Transimmunization for Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/21/2011
Morristown Memorial Hospital
mi
from
Morristown, NJ
Click here to add this to my saved trials
The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease
The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease: A Prospective Cohort Study
Status: Enrolling
Updated:  6/7/2011
John Muir Health
mi
from
Concord, CA
The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease
The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease: A Prospective Cohort Study
Status: Enrolling
Updated: 6/7/2011
John Muir Health
mi
from
Concord, CA
Click here to add this to my saved trials
The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease
The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease: A Prospective Cohort Study
Status: Enrolling
Updated:  6/7/2011
Seton Pulmonary & Cardiac Rehabilitation
mi
from
Daly City, CA
The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease
The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease: A Prospective Cohort Study
Status: Enrolling
Updated: 6/7/2011
Seton Pulmonary & Cardiac Rehabilitation
mi
from
Daly City, CA
Click here to add this to my saved trials
The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease
The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease: A Prospective Cohort Study
Status: Enrolling
Updated:  6/7/2011
Yale University School of Medicine
mi
from
New Haven, CT
The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease
The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease: A Prospective Cohort Study
Status: Enrolling
Updated: 6/7/2011
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease
The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease: A Prospective Cohort Study
Status: Enrolling
Updated:  6/7/2011
Duke Univ Med Ctr
mi
from
Durham, NC
The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease
The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease: A Prospective Cohort Study
Status: Enrolling
Updated: 6/7/2011
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease
The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease: A Prospective Cohort Study
Status: Enrolling
Updated:  6/7/2011
Inova Fairfax Hospital
mi
from
Falls Church, VA
The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease
The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease: A Prospective Cohort Study
Status: Enrolling
Updated: 6/7/2011
Inova Fairfax Hospital
mi
from
Falls Church, VA
Click here to add this to my saved trials
Celecoxib in Preventing Lung Cancer in Former Heavy Smokers
Lung Cancer Chemoprevention With Celecoxib In Ex-Smokers
Status: Enrolling
Updated:  6/16/2011
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Celecoxib in Preventing Lung Cancer in Former Heavy Smokers
Lung Cancer Chemoprevention With Celecoxib In Ex-Smokers
Status: Enrolling
Updated: 6/16/2011
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Breath Test for Early Detection of Lung Cancer
Breath Test Assay for the Adjunctive Detection of Lung Cancer
Status: Enrolling
Updated:  6/23/2011
Christiana Hospital
mi
from
Newark, DE
Breath Test for Early Detection of Lung Cancer
Breath Test Assay for the Adjunctive Detection of Lung Cancer
Status: Enrolling
Updated: 6/23/2011
Christiana Hospital
mi
from
Newark, DE
Click here to add this to my saved trials
Breath Test for Early Detection of Lung Cancer
Breath Test Assay for the Adjunctive Detection of Lung Cancer
Status: Enrolling
Updated:  6/23/2011
MD Anderson Cancer Center
mi
from
Orlando, FL
Breath Test for Early Detection of Lung Cancer
Breath Test Assay for the Adjunctive Detection of Lung Cancer
Status: Enrolling
Updated: 6/23/2011
MD Anderson Cancer Center
mi
from
Orlando, FL
Click here to add this to my saved trials
Breath Test for Early Detection of Lung Cancer
Breath Test Assay for the Adjunctive Detection of Lung Cancer
Status: Enrolling
Updated:  6/23/2011
New York University Medical Center
mi
from
New York, NY
Breath Test for Early Detection of Lung Cancer
Breath Test Assay for the Adjunctive Detection of Lung Cancer
Status: Enrolling
Updated: 6/23/2011
New York University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Breath Test for Early Detection of Lung Cancer
Breath Test Assay for the Adjunctive Detection of Lung Cancer
Status: Enrolling
Updated:  6/23/2011
Swedish Cancer Institute
mi
from
Seattle, WA
Breath Test for Early Detection of Lung Cancer
Breath Test Assay for the Adjunctive Detection of Lung Cancer
Status: Enrolling
Updated: 6/23/2011
Swedish Cancer Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Trial Comparing the Use of FLT PET to Standard CT to Assess Treatment Response of Neoadjuvant Docetaxel and Cisplatin in Stage IB-IIIA Resectable NSCLC
A Phase II Single-arm Trial Comparing the Use of FLT PET to Standard Computed Tomography to Assess Treatment Response of Neoadjuvant Docetaxel and Cisplatin in Stage IB-IIIA Resectable Non-small Lung Cancer.
Status: Enrolling
Updated:  7/19/2011
Georgetown University Hospital
mi
from
Washington,
Trial Comparing the Use of FLT PET to Standard CT to Assess Treatment Response of Neoadjuvant Docetaxel and Cisplatin in Stage IB-IIIA Resectable NSCLC
A Phase II Single-arm Trial Comparing the Use of FLT PET to Standard Computed Tomography to Assess Treatment Response of Neoadjuvant Docetaxel and Cisplatin in Stage IB-IIIA Resectable Non-small Lung Cancer.
Status: Enrolling
Updated: 7/19/2011
Georgetown University Hospital
mi
from
Washington,
Click here to add this to my saved trials
Trial Comparing the Use of FLT PET to Standard CT to Assess Treatment Response of Neoadjuvant Docetaxel and Cisplatin in Stage IB-IIIA Resectable NSCLC
A Phase II Single-arm Trial Comparing the Use of FLT PET to Standard Computed Tomography to Assess Treatment Response of Neoadjuvant Docetaxel and Cisplatin in Stage IB-IIIA Resectable Non-small Lung Cancer.
Status: Enrolling
Updated:  7/19/2011
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Trial Comparing the Use of FLT PET to Standard CT to Assess Treatment Response of Neoadjuvant Docetaxel and Cisplatin in Stage IB-IIIA Resectable NSCLC
A Phase II Single-arm Trial Comparing the Use of FLT PET to Standard Computed Tomography to Assess Treatment Response of Neoadjuvant Docetaxel and Cisplatin in Stage IB-IIIA Resectable Non-small Lung Cancer.
Status: Enrolling
Updated: 7/19/2011
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Trial Comparing the Use of FLT PET to Standard CT to Assess Treatment Response of Neoadjuvant Docetaxel and Cisplatin in Stage IB-IIIA Resectable NSCLC
A Phase II Single-arm Trial Comparing the Use of FLT PET to Standard Computed Tomography to Assess Treatment Response of Neoadjuvant Docetaxel and Cisplatin in Stage IB-IIIA Resectable Non-small Lung Cancer.
Status: Enrolling
Updated:  7/19/2011
Ohio State University James Cancer Hospital and Solove Research Institute
mi
from
Columbus, OH
Trial Comparing the Use of FLT PET to Standard CT to Assess Treatment Response of Neoadjuvant Docetaxel and Cisplatin in Stage IB-IIIA Resectable NSCLC
A Phase II Single-arm Trial Comparing the Use of FLT PET to Standard Computed Tomography to Assess Treatment Response of Neoadjuvant Docetaxel and Cisplatin in Stage IB-IIIA Resectable Non-small Lung Cancer.
Status: Enrolling
Updated: 7/19/2011
Ohio State University James Cancer Hospital and Solove Research Institute
mi
from
Columbus, OH
Click here to add this to my saved trials
Cyclin B1 Peptide-Pulsed Autologous Dendritic Cell Vaccine for Resectable Non-Small Cell Lung Cancer
A Pilot Study of Cyclin B1 Peptide-Pulsed Autologous Dendritic Cell Vaccine for Patients With Resectable Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  9/27/2011
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Cyclin B1 Peptide-Pulsed Autologous Dendritic Cell Vaccine for Resectable Non-Small Cell Lung Cancer
A Pilot Study of Cyclin B1 Peptide-Pulsed Autologous Dendritic Cell Vaccine for Patients With Resectable Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 9/27/2011
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer
A Phase I/II Trial of Temsirolimus and Pemetrexed in Recurrent/Refractory Non Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  10/6/2011
Washington University School of Medicine
mi
from
Saint Louis, MO
Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer
A Phase I/II Trial of Temsirolimus and Pemetrexed in Recurrent/Refractory Non Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 10/6/2011
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer
Phase I Study of Pazopanib in Combination With Vinorelbine in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer
Status: Enrolling
Updated:  10/19/2011
Northwestern University, Northwestern Medical Faculty Foundation
mi
from
Chicago, IL
Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer
Phase I Study of Pazopanib in Combination With Vinorelbine in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer
Status: Enrolling
Updated: 10/19/2011
Northwestern University, Northwestern Medical Faculty Foundation
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
A Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide In Patients With Unresectable Or Metastatic Soft Tissue Sarcoma or Malignant Mesothelioma
Status: Enrolling
Updated:  10/28/2011
Columbia University Medical Center
mi
from
New York, NY
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
A Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide In Patients With Unresectable Or Metastatic Soft Tissue Sarcoma or Malignant Mesothelioma
Status: Enrolling
Updated: 10/28/2011
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Trimodal Lung-Sparing Treatment of Pleural Mesothelioma
Phase II, A Study of Lung-Sparing Combined Modality Protocol for the Treatment for Malignant Pleural Mesothelioma: The Columbia Protocol
Status: Enrolling
Updated:  10/28/2011
Columbia University Medical Center
mi
from
New York, NY
Trimodal Lung-Sparing Treatment of Pleural Mesothelioma
Phase II, A Study of Lung-Sparing Combined Modality Protocol for the Treatment for Malignant Pleural Mesothelioma: The Columbia Protocol
Status: Enrolling
Updated: 10/28/2011
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma
A Two Stage, Open Label, Phase II Study of VELCADE Plus ELOXATIN in Previously Treated Patients With Malignant Pleural or Peritoneal Mesothelioma
Status: Enrolling
Updated:  10/28/2011
Columbia University Medical Center
mi
from
New York, NY
Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma
A Two Stage, Open Label, Phase II Study of VELCADE Plus ELOXATIN in Previously Treated Patients With Malignant Pleural or Peritoneal Mesothelioma
Status: Enrolling
Updated: 10/28/2011
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Carcinoma (NSCLC)
A Phase 2 Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Squamous, Non-Small Cell Lung Carcinoma
Status: Enrolling
Updated:  10/28/2011
North Shore University Hospital
mi
from
Manhasset, NY
A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Carcinoma (NSCLC)
A Phase 2 Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Squamous, Non-Small Cell Lung Carcinoma
Status: Enrolling
Updated: 10/28/2011
North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Carcinoma (NSCLC)
A Phase 2 Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Squamous, Non-Small Cell Lung Carcinoma
Status: Enrolling
Updated:  10/28/2011
Columbia University Medical Center
mi
from
New York, NY
A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Carcinoma (NSCLC)
A Phase 2 Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Squamous, Non-Small Cell Lung Carcinoma
Status: Enrolling
Updated: 10/28/2011
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
A Phase II Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/7/2011
Rush University Medical Center
mi
from
Chicago, IL
A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
A Phase II Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/7/2011
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
A Phase II Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/7/2011
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
A Phase II Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/7/2011
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  11/7/2011
Northwest Alabama Cancer Center, PC
mi
from
Muscle Shoals, AL
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 11/7/2011
Northwest Alabama Cancer Center, PC
mi
from
Muscle Shoals, AL
Click here to add this to my saved trials
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  11/7/2011
Sharp Memorial Hospital
mi
from
San Diego, CA
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 11/7/2011
Sharp Memorial Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  11/7/2011
University of Chicago Medical Center
mi
from
Chicago, IL
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 11/7/2011
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  11/7/2011
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 11/7/2011
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  11/7/2011
St. Agnes Hospital
mi
from
Baltimore, MD
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 11/7/2011
St. Agnes Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  11/7/2011
Massachusetts General Hospital
mi
from
Boston, MA
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 11/7/2011
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  11/7/2011
University of Minnesota Medical Center, Fairview
mi
from
Minneapolis, MN
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 11/7/2011
University of Minnesota Medical Center, Fairview
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  11/7/2011
Park Nicollet Clinic - Cancer Center St. Louis Park
mi
from
St. Louis Park, MN
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 11/7/2011
Park Nicollet Clinic - Cancer Center St. Louis Park
mi
from
St. Louis Park, MN
Click here to add this to my saved trials
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  11/7/2011
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 11/7/2011
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  11/7/2011
Cleveland Clinic Foundation, Taussig Cancer Center
mi
from
Cleveland, OH
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 11/7/2011
Cleveland Clinic Foundation, Taussig Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  11/7/2011
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 11/7/2011
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  11/7/2011
South Texas Institute of Cancer
mi
from
Corpus Christi, TX
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 11/7/2011
South Texas Institute of Cancer
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  11/7/2011
William Osler Health Center
mi
from
Brampton,
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 11/7/2011
William Osler Health Center
mi
from
Brampton,
Click here to add this to my saved trials
Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
A Phase 2A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Immune Response, Safety and Efficacy of HS-110 in Combination With Erlotinib vs. Erlotinib as a Single Agent in Patients With Advanced, Non-EGFR Mutated Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/4/2012
Mary Crowley Cancer Research Centers
mi
from
Dallas, TX
Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
A Phase 2A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Immune Response, Safety and Efficacy of HS-110 in Combination With Erlotinib vs. Erlotinib as a Single Agent in Patients With Advanced, Non-EGFR Mutated Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/4/2012
Mary Crowley Cancer Research Centers
mi
from
Dallas, TX
Click here to add this to my saved trials
A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)
A Therapeutic Trial of Afatinib in the Neoadjuvant Setting. Molecular Effects of Afatinib: A Window of Opportunity Trial In Early Stage NSCLC
Status: Enrolling
Updated:  1/31/2012
Medical University of South Carolina
mi
from
Charleston, SC
A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)
A Therapeutic Trial of Afatinib in the Neoadjuvant Setting. Molecular Effects of Afatinib: A Window of Opportunity Trial In Early Stage NSCLC
Status: Enrolling
Updated: 1/31/2012
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Race, Ethnicity, and Diffuse Parenchymal Lung Disease
Determinants of Outcome in Diffuse Parenchymal Lung Disease
Status: Enrolling
Updated:  2/8/2012
Columbia University Medical Center
mi
from
New York, NY
Race, Ethnicity, and Diffuse Parenchymal Lung Disease
Determinants of Outcome in Diffuse Parenchymal Lung Disease
Status: Enrolling
Updated: 2/8/2012
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  3/13/2012
City of Hope
mi
from
Duarte, CA
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 3/13/2012
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials